FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4244911191> ?p ?o ?g. }

• W4244911191 endingPage "4856" @default.
• W4244911191 startingPage "4851" @default.
• W4244911191 abstract "L-163,255 is a potent orally active spiropiperidine GH secretagogue. When administered iv or orally, L-163,255 caused GH to be increased in a dose-related manner, with a return to baseline by 90 min. After iv administrations of saline and L-163,255 at 1, 3, and 10 micrograms/kg, GH areas under the curves (GH AUCs) over 120 min were 377 +/- 136, 1151 +/- 413 (P < 0.05), 795 +/- 413 (P = NS), and 1770 +/- 416 ng.min/ml (P < 0.01), and peak GH concentrations were 8 +/- 3, 16 +/- 7 (P = NS), 17 +/- 5 (P = NS), and 43 +/- 12 ng/ml (P < 0.01), respectively. No changes in plasma cortisol concentrations were noted. After oral administrations at 3, 10, and 30 micrograms/kg, GH AUCs over 180 min were 1133 +/- 154, 1246 +/- 129 (P = NS), and 1551 +/- 210 ng.min/ml (P = NS), and peak GH concentrations were 7 +/- 2, 11 +/- 3 (P = NS), and 23 +/- 6 ng/ml (P < 0.01), respectively. After administration in feed, L-163,255 caused a dose-related increase in GH, with an initial peak observed at 60 min for both 30 and 300 micrograms/kg dose groups, and remained elevated above baseline through 180 min for the high dose group only. GH AUCS for 180 min posttreatment were 929 +/- 134 and 1897 +/- 244 ng.min/ml, and peak GH concentrations were 9 +/- 2 and 22 +/- 4 ng/ml for the 30 and 300 micrograms/kg doses prepared in 150 g feed, respectively. When provided in feed ad libitum over the 72-h period, mean plasma insulin-like growth factor I levels increased 15%, 62% (P < 0.01), and 109% (P < 0.01) in the untreated, treated with L-163,255 at 360 ppm, or treated with porcine somatotropin groups, respectively. Repeated iv administration of L-163,255 at 1 mg/kg once daily over 14 days resulted in an initial marked GH response, followed by a much reduced, but significantly elevated, GH response over the saline control values on subsequent treatment days. Repeated iv treatments with L-163,255 also resulted in an elevated insulin-like growth factor I level (approximately 60%) over that in saline controls. Compared to those in saline controls, plasma cortisol concentrations tended to be increased after the initial dose of L-163,255, but no significant increases were noted on days 7 and 14 in the L-163,255 group. The results of these studies indicate that L-163,255 is an orally active GH secretagogue suitable for long term efficacy studies in swine." @default.
• W4244911191 created "2022-05-12" @default.
• W4244911191 creator A5075075424 @default.
• W4244911191 date "1996-11-01" @default.
• W4244911191 modified "2023-09-24" @default.
• W4244911191 title "Growth hormone (GH) and insulin-like growth factor I responses after treatments with an orally active GH secretagogue L-163,255 in swine" @default.
• W4244911191 doi "https://doi.org/10.1210/en.137.11.4851" @default.
• W4244911191 hasPublicationYear "1996" @default.
• W4244911191 type Work @default.
• W4244911191 citedByCount "4" @default.
• W4244911191 countsByYear W42449111912014 @default.
• W4244911191 crossrefType "journal-article" @default.
• W4244911191 hasAuthorship W4244911191A5075075424 @default.
• W4244911191 hasBestOaLocation W42449111911 @default.
• W4244911191 hasConcept C126322002 @default.
• W4244911191 hasConcept C134018914 @default.
• W4244911191 hasConcept C170493617 @default.
• W4244911191 hasConcept C185592680 @default.
• W4244911191 hasConcept C2775960820 @default.
• W4244911191 hasConcept C2777397205 @default.
• W4244911191 hasConcept C2779306644 @default.
• W4244911191 hasConcept C2779357093 @default.
• W4244911191 hasConcept C2780161494 @default.
• W4244911191 hasConcept C2780689927 @default.
• W4244911191 hasConcept C2984496839 @default.
• W4244911191 hasConcept C71315377 @default.
• W4244911191 hasConcept C71924100 @default.
• W4244911191 hasConceptScore W4244911191C126322002 @default.
• W4244911191 hasConceptScore W4244911191C134018914 @default.
• W4244911191 hasConceptScore W4244911191C170493617 @default.
• W4244911191 hasConceptScore W4244911191C185592680 @default.
• W4244911191 hasConceptScore W4244911191C2775960820 @default.
• W4244911191 hasConceptScore W4244911191C2777397205 @default.
• W4244911191 hasConceptScore W4244911191C2779306644 @default.
• W4244911191 hasConceptScore W4244911191C2779357093 @default.
• W4244911191 hasConceptScore W4244911191C2780161494 @default.
• W4244911191 hasConceptScore W4244911191C2780689927 @default.
• W4244911191 hasConceptScore W4244911191C2984496839 @default.
• W4244911191 hasConceptScore W4244911191C71315377 @default.
• W4244911191 hasConceptScore W4244911191C71924100 @default.
• W4244911191 hasIssue "11" @default.
• W4244911191 hasLocation W42449111911 @default.
• W4244911191 hasOpenAccess W4244911191 @default.
• W4244911191 hasPrimaryLocation W42449111911 @default.
• W4244911191 hasRelatedWork W1990664757 @default.
• W4244911191 hasRelatedWork W1999569700 @default.
• W4244911191 hasRelatedWork W2001044066 @default.
• W4244911191 hasRelatedWork W2033468788 @default.
• W4244911191 hasRelatedWork W2118753359 @default.
• W4244911191 hasRelatedWork W2135939157 @default.
• W4244911191 hasRelatedWork W4238637842 @default.
• W4244911191 hasRelatedWork W4244911191 @default.
• W4244911191 hasRelatedWork W4249391924 @default.
• W4244911191 hasRelatedWork W4255621366 @default.
• W4244911191 hasVolume "137" @default.
• W4244911191 isParatext "false" @default.
• W4244911191 isRetracted "false" @default.
• W4244911191 workType "article" @default.